Suppr超能文献

骨质疏松症研究VII. 17β-羟基-4-雌烯-3-酮17-癸酸酯对实验性骨质疏松症的影响。

Studies on osteoporosis VII. Effect of 17 beta-hydroxy-4-estren-3-one 17-decanoate on experimental osteoporosis.

作者信息

Robin J C, Suh O W, Ambrus J L

出版信息

Steroids. 1982 Aug;40(2):125-32. doi: 10.1016/0039-128x(82)90026-5.

Abstract

Total body neutron activation analysis was employed to measure total calcium in C3H/St (Ha) female mice. Ninety-nine percent of total body calcium is in bone and loss of calcium was used as an index of osteoporosis. Heparin (500 U/kg B.I.D.) treatment for three months resulted in significant osteoporosis. 17 beta-Hydroxy-4-estren-3-one 17-decanoate 1.5 mg/kg or 4 mg/kg twice monthly prevented this heparin accelerated osteoporosis. The results suggest that 17 beta-hydroxy-4-estren-3-one 17-decanoate may be capable of preventing bone loss and partially increasing bone mass in patients exposed to osteoporosis inducing regimens.

摘要

采用全身中子活化分析法测量C3H/St(Ha)雌性小鼠的总钙含量。全身钙的99%存在于骨骼中,钙的流失被用作骨质疏松症的指标。肝素(500 U/kg,每日两次)治疗三个月导致明显的骨质疏松症。17β-羟基-4-雌烯-3-酮17-癸酸酯以1.5 mg/kg或4 mg/kg的剂量每月两次给药可预防这种肝素加速的骨质疏松症。结果表明,17β-羟基-4-雌烯-3-酮17-癸酸酯可能能够预防接受诱发骨质疏松症方案治疗的患者的骨质流失并部分增加骨量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验